Investor Presentation - First Six Months of 2021
63
Investor presentation First six months of 2021
Novo NordiskⓇ
In STEP 8, semaglutide 2.4 mg showed weight loss of 17.1%
compared to 6.6% with liraglutide 3.0 mg
0
STEP 8 observed mean change in body weight¹
Mean baseline body weight: 104.5 kg
Statistically significant weight loss with sema 2.4 mg vs lira 3.0 mg
Mean baseline body weight: 104.5 kg
0
% change in body weight
S
-10
-15
-20
05
Sema 2.4 mg
Lira 3.0 mg
Placebo
10 15 20 25 30 35 40 45 50 55 60 65 68
% change in body weight
-5
-10
-6.6
-1.8
-15
-17.1*
-20
Sema 2.4 mg
Lira 3.0 mg
Placebo
1 Observed data for the on-treatment period; *p-value <0.0001 vs lira 3.0 mg; % change in body weight measured as change from baseline
Data shown is the trial product estimand; Sema: semaglutide; Lira: liraglutideView entire presentation